Proportion of participants with detectable HBV‐DNA in serum or plasma (at maximum · chronic hepatitis B
It is very uncertain whether radix Sophorae flavescentis changes surrogate outcomes: Proportion of participants with detectable… compared with no intervention or placebo (very low certainty).
1 finding from 1 review
All‐cause mortality · people with paracetamol (acetaminophen) overdose
It is very uncertain whether charcoal haemoperfusion changes mortality compared with no intervention (very low certainty).
1 finding from 1 review
All‐cause mortality · people with paracetamol (acetaminophen) overdose
It is very uncertain whether cysteamine changes mortality compared with no intervention (very low certainty).
1 finding from 1 review
Hepatotoxicity (aspartate aminotransferase > 1000 IU/L) · people with paracetamol (acetaminophen) overdose
Cysteamine may leads to lower hepatotoxicity (aspartate aminotransferase > 1000 IU/L) compared with no intervention (low certainty).
1 finding from 1 review
All‐cause mortality · people with hepatorenal syndrome
Terlipressin may leads to lower mortality compared with placebo or no intervention (low certainty).
1 finding from 1 review
Hepatorenal syndrome · people with hepatorenal syndrome
Terlipressin may leads to lower hepatorenal syndrome compared with placebo or no intervention (low certainty).
1 finding from 1 review
Serious adverse events · people with hepatorenal syndrome
Terlipressin showed no clear difference in serious adverse events compared with placebo or no intervention (low certainty).
1 finding from 1 review
Serious adverse events: cardiovascular events · people with hepatorenal syndrome
Terlipressin may leads to higher serious cardiovascular adverse events compared with placebo or no intervention (low certainty).
1 finding from 1 review
Abdominal pain · people with hepatorenal syndrome
Terlipressin showed no clear difference in abdominal pain compared with placebo or no intervention (low certainty).
1 finding from 1 review
Diarrhoea · people with hepatorenal syndrome
Terlipressin may leads to higher diarrhoea compared with placebo or no intervention (low certainty).
1 finding from 1 review
All‐cause mortality · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
Serious adverse events (proportion) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
Serious adverse events (number of events) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether thiazolidinediones changes serious adverse events (number of events) compared with no intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with non‐alcohol‐related fatty liver disease (NAFLD)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
Serious adverse events (number of events) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether antioxidants changes serious adverse events (number of events) compared with no intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with non‐alcohol‐related fatty liver disease (NAFLD)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether bile acids changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether bile acids changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether bile acids changes serious adverse events (number of events) compared with no intervention (very low certainty).
1 finding from 1 review